Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
- Citation:
- Lancet Haematol vol 10 (10) e825-e837
- Year:
- 2023
- Type:
- Manuscript
- Funding:
- AFT
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub-ppub
- Note:
- Pharmas:
- Janssen Oncology
- Grants:
- Corr. Author:
- Authors:
- Peter M Voorhees Douglas W Sborov Jacob Laubach Jonathan L Kaufman Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J Costa Larry D Anderson Nitya Nathwani Nina Shah Naresh Bumma Yvonne A Efebera Sarah A Holstein Caitlin Costello Andrzej Jakubowiak Tanya M Wildes Robert Z Orlowski Kenneth H Shain Andrew J Cowan Shira Dinner Huiling Pei Annelore Cortoos Sharmila Patel Thomas S Lin Saad Z Usmani Paul G Richardson
- Networks:
- CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OH008, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: